Vincerx Pharma, Inc.
VINC
$-0.02
Change (1 day)
$9.37
Year High
$0.26
Year Low
Categories
Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. Its lead product candidate is VIP152, a cyclin-dependent kinase-9 inhibitor for treating patients with advanced cancer. The company's preclinical stage product candidates include VIP217, an oral PTEFb/CDK9 inhibitor; VIP236, a small molecule drug conjugate to treat solid tumors; and VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is headquartered in Palo Alto, California.
Vincerx Pharma, Inc. (VINC) - Company Outlook
Company Outlook
| Year | Receivables | Debt | Liabilities | Assets | Current Assets |
|---|---|---|---|---|---|
| 2023 | -10,280,000 | 7 M | 18.22 M | 14.73 M | |
| 2022 | 1.37 M | -8,227,000 | 11.62 M | 59.29 M | 55.96 M |
| 2021 | -107,285,000 | 17.36 M | 117.68 M | 111.84 M | |
| 2020 | -61,792,000 | 5.51 M | 63.19 M | 63.11 M | |
| 2019 | -684,708 | 44 K | 1,000 | 791.04 K |